Browsing by title
Now showing items 1659-1678 of 4188
-
Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(aEuro)
(OXFORD UNIV PRESS, 2015-09) -
Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation
(PERGAMON-ELSEVIER SCIENCE LTD, 2008-03)Aberrant growth factor production is a prevalent mechanism in tumourigenesis. If T-cells responded positively to a cancer-derived cytokine, this might result in selective enhancement of function within the tumour ... -
Health economic impact of liquid biopsies in cancer management.
(2018-12)<h4>Introduction</h4>Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are ... -
Health-related quality of life among cancer patients in their last year of life: results from the PROFILES registry.
(2018-10)PURPOSE:The aim of this study was to assess health-related quality of life (HRQoL) in the last year of life of cancer patients stratified by four periods of time before death. PATIENTS AND METHODS:Between 2008 and 2015, ... -
Health-related quality of life around the time of diagnosis in patients with bladder cancer.
(2019-12)<h4>Objectives</h4>To quantify the health-related quality of life (HRQoL) of patients with bladder cancer around the time of diagnosis and to test the hypotheses of a two-factor model for the HRQoL questionnaire ... -
Health-related quality of life results from the phase III CheckMate 067 study.
(2017-09)<h4>Background</h4>Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, ... -
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
(2017-12)<h4>Background</h4>In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung ... -
HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients
(Elsevier BV, 2017-06) -
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.
(2019-04)<h4>Background</h4>BRCA1/2 mutations confer high lifetime risk of breast cancer, although other factors may modify this risk. Whether height or body mass index (BMI) modifies breast cancer risk in BRCA1/2 mutation carriers ... -
Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization.
(2015-11)<h4>Background</h4>Epidemiological studies have linked adult height with breast cancer risk in women. However, the magnitude of the association, particularly by subtypes of breast cancer, has not been established. Furthermore, ... -
Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.
(2017-08)<h4>Background</h4>Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.<h4>Methods</h4>We ... -
Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.
(2017-02)<h4>Background</h4>Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; ... -
Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods
(OXFORD UNIV PRESS, 2005-03)Liver homogenates from rats fed tamoxifen (TAM) in the diet were shared among four different laboratories. TAM-DNA adducts were assayed by high pressure liquid chromatography-electrospray tandem mass spectrometry ... -
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
(2017-07)<h4>Background</h4>A meta-analysis of the effects of HER2 status, specifically within the first 2-3 years of adjuvant endocrine therapy, has the potential to inform patient selection for upfront aromatase inhibitor (AI) ... -
HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
(2018-04)Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). ...